Sam Waksal

(redirected from Samuel D. Waksal)
Also found in: Financial, Wikipedia.
Founder of the biopharmaceutical company ImClone who was convicted of insider trading
References in periodicals archive ?
6 million attributable to the withholding tax liability for Samuel D.
By achieving this milestone we have demonstrated the ability to manufacture clinical supply of IMC-C225 that meets the requirements of international regulatory authorities," stated Samuel D.
This seminal moment for ImClone Systems represents the efforts of not only the Company, but also the oncology community and most importantly the patients, who helped to advance the clinical understanding of IMC-C225," stated Samuel D.
The achievement of the patient randomization milestone in addition to the patient enrollment milestone is a testament to the effective working relationship we maintain with Merck KGaA," stated Samuel D.
The early achievement of this milestone exemplifies the strength of our Phase II data in refractory colorectal cancer and our well managed IMC-C225 clinical trials program," stated Samuel D.
Lily brings valuable leadership and experience in the regulatory aspects of moving an oncology program through clinical testing to product approval and onto the commercial market," stated Samuel D.
As ImClone Systems has pioneered research in this area, the attainment of this milestone in the BEC2 program is a significant event for the Company," stated Samuel D.
We are pleased to welcome Dan Lynch, with his strong financial background in the industry, to his new role at ImClone Systems," stated Samuel D.
Combination therapy has become the gold standard in the treatment of patients with cancer," stated Samuel D.